admin The CEO of AstraZeneca Pascal Soroit has claimed that the vaccine being manufactured by his company will offer 95% protection which is no less than Pfizer and Moderna vaccines. He further said that the scientists had aced the formula required and therefore the amazing results.
AstraZeneca which is a British-Swedish pharmaceutical giant has not released any data verifying this whatsoever. But it is expected to release data on the same soon. Interim data of the vaccine trials were able to prove 70% efficacy by giving the volunteers two doses of the vaccine.
The Pfizer vaccine has already been authorized for emergency use in many parts of the world including the United States and the European Union with a proved efficacy of 95% but one problem that is being encountered by this vaccine is the extremely low temperatures that it requires for storage. Moreover, certain side-effects have also been noted in some of the recipients and therefore people prone to allergy reactions have been told to avoid taking the vaccine for now.
The CEO said that the vaccine should be effective in all probability on the mutations and different strains being reported all across the world. It is being speculated that the British health regulator will clear the AstraZeneca vaccine by the end of the current week.
The production of this vaccine will primarily be done in India and is one of the potential vaccines that will be administered to the people of India. This AstraZeneca vaccination will also be cheaper than both the Pfizer and Moderna placed at $20 and $25 respectively. This vaccine dose will be placed at $2.5 per dose which is a substantial price drop, thus making it viable for the poor countries to provide vaccination to their population as well.
The world is now looking at a number of potential vaccines and vaccination drives have begun in different parts of the world, most governments are trying to provide vaccinations in an effective and pre-planned manner by providing them first to the healthcare workers, the elderly, frontline workers and so on.
Magazine 
